CHENGDU, China, Aug. 28, 2024 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update. Rapid development of our pipeline productsStapokibart (CM310) (IL-4Ra antibody)CMG901/AZD0901 (Claudin 18.2 ADC)CM313 (CD38 antibody)CM326 (TSLP antibody)CM355/ICP-B02 (CD20xCD3 bispecific antibody)CM336 (BCMAxCD3 bispecific antibody)CM350 (GPC3xCD3 bispecific antibody)CM369/ICP-B05 (CCR8 antibody)CM383 (Aß protofibrils antibody)CM380 (GPRC5DxCD3 bispecific antibody)Financial and Business Highlights View original content:https://www.prnewswire.co.uk/news-releases/keymed-biosciences-announces-interim-results-for-first-half-of-2024-302232637.html
Seguici su